NEW YORK (GenomeWeb News) – Myriad Genetics today said that its Myriad RBM subsidiary has formed a research collaboration with DaVita Labs to discover protein-based biomarkers that could be used to benefit dialysis patients.
The firms said that the primary focus of the collaboration will be on markers that predict vascular access failure.
DaVita Labs, a unit of DaVita HealthCare Partners, will provide specimens from its biorepository, while Myriad RBM will use its DiscoveryMAP platform to analyze the samples for potential use as biomarkers. Myriad expects to begin processing specimens for the collaboration in its fiscal year 2014, which begins July 1.
"We have extensive experience with research in kidney disease and inflammatory markers that we believe could increase the quality of care for dialysis patients," Craig Benson, president of Myriad RBM, said in a statement.
Financial and other terms of the agreement were not disclosed.